Effect of vitamin C and L-NMMA on the inotropic response to dobutamine in patients with heart failure

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 289, Issue 6 58-6, 2005, Pages

  Mak, Susanna ^a   Overgaard, Christopher B ^a   Newton, Gary E ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Antioxidants; Nitric oxide

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ASCORBIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOBUTAMINE; LOOP DIURETIC AGENT; N(G) METHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE CONTRACTILITY; HUMAN; INOTROPISM; LEFT CORONARY ARTERY; MALE; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL;

ASCORBIC ACID; BLOOD PRESSURE; CARDIOTONIC AGENTS; DOBUTAMINE; DRUG COMBINATIONS; HEART FAILURE, CONGESTIVE; HEART RATE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL CONTRACTION; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OMEGA-N-METHYLARGININE; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 28144438893     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.00453.2005     Document Type: Article

References (36)

1. Bolli R. Basic and clinical aspects of myocardial stunning. Prog Cardiovasc Dis 40: 477-516, 1998.
2. Charlat MI, O'Neill PG, Egan JM, Abernethy DR, Michael LH, Myers ML, Roberts R, and Bolli R. Evidence for a pathogenetic role of xanthine oxidase in the "stunned" myocardium. Am J Physiol Heart Circ Physiol 252: H566-H577, 1987.
3. Cotton JM, Kearney MT, MacCarthy PA, Grocott-Mason RM, McClean DR, Heymes C, Richardson PJ, and Shah AM. Effects of nitric oxide synthase inhibition on basal function and the force-frequency relationship in the normal and failing human heart in vivo. Circulation 104: 2318-2323, 2001.
4. Dhalla AK and Singal PK. Antioxidant changes in hypertrophied and failing guinea pig hearts. Am J Physiol Heart Circ Physiol 266: H1280-H1285, 1994.
5. Ekelund UE, Harrison RW, Shokek O, Thakkar RN, Tunin RS, Senzaki H, Kass DA, Marban E, and Hare JM. Intravenous allopurinol decreases myocardial oxygen consumption and increases mechanical efficiency in dogs with pacing-induced heart failure. Circ Res 85: 437-445, 1999.
6. Gealekman O, Abassi Z, Rubinstein I, Winaver J, and Binah O. Role of myocardial inducible nitric oxide synthase in contractile dysfunction and β-adrenergic hyporesponsiveness in rats with experimental volume-overload heart failure. Circulation 105: 236-243, 2002.
7. Givertz MM, Sawyer DB, and Colucci WS. Antioxidants and myocardial contractility: illuminating the "dark side" of β-adrenergic receptor activation? Circulation 103: 782-783.
8. Goldhaber JI, Ji S, Lamp ST, and Weiss JN. Effects of exogenous free radicals on electromechanical function and metabolism in isolated rabbit and guinea pig ventricle. J Clin Invest 83: 1800-1809, 1989.
9. Gryglewski RJ, Palmer RM, and Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 320: 454-456, 1986.
10. Hare JM, Givertz MM, Creager MA, and Colucci WS. Increased sensitivity to nitric oxide synthase inhibition in patients with heart failure. Potentiation of β-adrenergic inotropic responsiveness. Circulation 97: 161-166, 1998.
11. Hare JM, Loh E, Creager MA, and Colucci WS. Nitric oxide inhibits the positive inotropic response to β-adrenergic stimulation in humans with left ventricular dysfunction. Circulation 92: 2198-2203, 1995.
12. Hare JM. Nitric oxide and excitation-contraction coupling. J Mol Cell Cardiol 35: 719-729, 2003.
13. Hare JM. Nitroso-redox balance in the cardiovascular system. N Engl J Med 351: 2112-2114, 2004.
14. Jackson TS, Xu A, Vita JA, and Keaney JF. Ascorbate prevents the interaction of superoxide and nitric oxide only at very high physiological concentrations. Circ Res 83: 916-922, 1998.
15. 2+ pump by oxygen free radicals. Am J Physiol Heart Circ Physiol 257: H804-H811, 1989.
16. Kelly RA, Balligand JL, and Smith TW. Nitric oxide and cardiac function. Circ Res 79: 363-380, 1996.
17. Mak S, Lehotay DC, Yazdanpanah M, Azevedo ER, Liu PP, and Newton GE. Unsaturated aldehydes including 4-OH-nonenal are elevated in patients with congestive heart failure. J Card Fail 6: 108-114, 2000.
18. Mak S and Newton GE. Vitamin C augments the inotropic response to dobutamine in humans with normal left ventricular function. Circulation 103: 826-830, 2001.
19. Mak S and Newton GE. The oxidative stress hypothesis of congestive heart failure: radical thoughts. Chest 120: 2035-2046.
20. Mak S and Newton GE. Redox modulation of the inotropic response to dobutamine is impaired in patients with heart failure. Am J Physiol Heart Circ Physiol 286: H789-H795, 2004.
21. Massion PB, Feron O, Dessy C, and Balligand JL. Nitric oxide and cardiac function: ten years after, and continuing. Circ Res 93: 388-398, 2003.
22. May JM. How does ascorbic acid prevent endothelial dysfunction? Free Rad Biol Med 28: 1421-1429, 2000.
23. Mayer B and Andrew P. Nitric oxide synthases: catalytic function and progress towards selective inhibition. Arch Pharmacol 358: 127-133, 1998.
24. Persad S, Takeda S, Panza JA, and Dhalla NS. β-Adrenoceptor-linked signal transduction in ischemic-reperfused heart and scavenging of oxyradicals. J Mol Cell Cardiol 29: 545-558, 1997.
25. Persad S, Elimban V, Kaila J, and Dhalla NS. Biphasic alterations in cardiac β-adrenoceptor signal transduction mechanism due to oxyradicals. J Pharmacol Exp Ther 282: 1623-1631, 1997.
26. Saavedra WF, Paolocci N, St John ME, Skaf MW, Stewart GC, Xie JS, Harrison RW, Zeichner J, Mudrick D, Marban E, Kass DA, and Hare JM. Imbalance between xanthine oxidase and nitric oxide synthase signaling pathways underlies mechanoenergetic uncoupling in the failing heart. Circ Res 90: 297-304.
27. Schrier GM and Hess ML. Quantitative identification of superoxide anion as a negative inotropic species. Am J Physiol Heart Circ Physiol 255: H138-H143, 1988.
28. Sherman DL, Keaney JF, Biegelson ES, Duffy SJ, Coffman JD, and Vita JA. Pharmacological concentrations of ascorbic acid are required for the beneficial effect on endothelial vasomotor function in hypertension. Hypertension 35: 936-941, 2000.
29. Shinke T, Takaoka H, Takeuchi M, Hata K, Kawai H, Okubo H, Kijima Y, Murata T, and Yokoyama M. Nitric oxide spares myocardial oxygen consumption through attenuation of contractile response to β-adrenergic stimulation in patients with idiopathic dilated cardiomyopathy. Circulation 101: 1925-1930.
30. Stamler JS, Lamas S, and Fang FC. Nitrosylation. The prototypic redox-based signaling mechanism. Cell 106: 675-683, 2001.
31. Trochu JN, Bouhour JB, Kaley G, and Hintze TH. Role of endothelium-derived nitric oxide in the regulation of cardiac oxygen metabolism: implications in health and disease. Circ Res 87: 1108-1117, 2000.
32. Ukai T, Cheng CP, Tachibana H, Igawa A, Zhang ZS, Cheng HJ, and Little WC. Allopurinol enhances the contractile response to dobutamine and exercise in dogs with pacing-induced heart failure. Circulation 103: 750-755, 2001.
33. Vatner DE, Kiuchi K, Manders WT, and Vatner SF. Effects of coronary arterial reperfusion on β-adrenergic receptor-adenylyl cyclase coupling. Am J Physiol Heart Circ Physiol 264: H196-H204, 1993.
34. Wittstein IS, Kass DA, Pak PH, Maughan WL, Fetics B, and Hare JM. Cardiac nitric oxide production due to angiotensin-converting enzyme inhibition decreases β-adrenergic myocardial contractility in patients with dilated cardiomyopathy. J Am Coll Cardiol 38: 429-435.
35. 2+-ATPase function by direct attack on the ATP binding site. Circ Res 80: 76-81, 1997.
36. 2+ transients. Circulation 109: 1886-1891, 2004.